
INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES

(p-ISSN: 2348-5213; e-ISSN: 2348-5221)

www.ijcreps.com

(A Peer Reviewed, Referred, Indexed and Open Access Journal)

DOI: 10.22192/ijcreps

Coden: IJCROO(USA)

Volume 11, Issue 5- 2024

Review Article



DOI: <http://dx.doi.org/10.22192/ijcreps.2024.11.05.002>

Aplastic Anemia in HIV: Role of Oxidative Stress and Inflammation

***Emmanuel Ifeanyi Obeagu¹ and Teddy Charles Adias²**

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, Federal University Otuoke, Bayelsa State, Nigeria

ORCID: 0000-0001-7057

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com,

ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) represents a critical hematologic complication in individuals living with HIV, characterized by bone marrow failure and pancytopenia. The complex interplay between HIV infection, immune dysregulation, and antiretroviral therapy (ART) contributes to the pathogenesis of AA, with oxidative stress and inflammation emerging as key players in disease progression. This review examines the role of oxidative stress and inflammation in the context of HIV-associated AA, elucidating their impact on hematopoiesis and immune homeostasis. Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, exerts detrimental effects on bone marrow function in HIV-infected individuals with AA. Elevated ROS levels contribute to oxidative damage of hematopoietic stem and progenitor cells, compromising their survival and differentiation capacity. Concurrently, chronic inflammation associated with HIV infection exacerbates bone marrow dysfunction by promoting immune dysregulation and immune-mediated destruction of hematopoietic cells. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), inhibit hematopoiesis and impair the bone marrow microenvironment, further exacerbating pancytopenia. Therapeutic strategies targeting oxidative stress and inflammation hold promise for improving outcomes in HIV-associated AA. Antioxidant therapies, including N-acetylcysteine (NAC) and alpha-lipoic acid (ALA), aim to restore redox balance and mitigate oxidative damage in the bone marrow. Similarly, anti-inflammatory agents such as corticosteroids and TNF- α inhibitors suppress pro-inflammatory cytokine production, attenuating immune-mediated hematopoietic cell destruction. Additionally, advancements in hematopoietic growth factors and stem cell transplantation offer alternative approaches to restore hematopoietic function and alleviate pancytopenia in select patients.

Keywords: Aplastic Anemia, HIV, Oxidative Stress, Inflammation, Hematopoiesis, Immune Dysregulation, Antiretroviral Therapy

Introduction

Aplastic anemia (AA) represents a severe and often life-threatening hematologic disorder characterized by hypocellular bone marrow and peripheral blood cytopenias, including anemia, neutropenia, and thrombocytopenia.¹ In the context of HIV infection, AA poses a significant clinical challenge due to the intricate interplay between the virus, immune dysregulation, and bone marrow function. While the incidence of AA in HIV-infected individuals is relatively low compared to other hematologic complications, its impact on morbidity and mortality remains substantial. Understanding the underlying pathogenesis of AA in HIV is crucial for developing effective therapeutic strategies to mitigate its progression and improve patient outcomes.²⁻³ HIV infection is associated with a myriad of hematologic abnormalities, including cytopenias, bone marrow suppression, and dysregulated immune responses. The virus directly affects bone marrow function by infecting hematopoietic progenitor cells and bone marrow stromal cells, leading to impaired hematopoiesis. Additionally, chronic immune activation and dysregulation, characteristic of HIV infection, contribute to the pathogenesis of AA by promoting inflammatory cytokine production and autoimmune mechanisms. The use of antiretroviral therapy (ART) further complicates the clinical management of AA, as certain antiretroviral drugs can induce hematologic toxicity and exacerbate bone marrow suppression.⁴⁻⁵

Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, has emerged as a key pathogenic mechanism in HIV-associated AA. Elevated levels of ROS in HIV-infected individuals contribute to oxidative damage of hematopoietic stem and progenitor cells, impairing their function and survival. Moreover, chronic inflammation, driven by pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), further exacerbates bone marrow dysfunction and immune-mediated hematopoietic cell destruction.

The intricate interplay between oxidative stress, inflammation, and bone marrow failure underscores the need for targeted therapeutic interventions to address these underlying pathogenic mechanisms.⁶⁻⁷ This review aims to provide a comprehensive overview of the role of oxidative stress and inflammation in the pathogenesis of AA in the context of HIV infection.

Role of Oxidative Stress

Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, plays a critical role in the pathogenesis of aplastic anemia (AA) among individuals living with HIV. This oxidative imbalance arises from various sources, including viral replication, immune activation, and antiretroviral therapy (ART), culminating in damage to hematopoietic stem and progenitor cells and impairment of bone marrow function.⁶

Mechanisms of Oxidative Stress in HIV-Associated AA

- 1. Viral Replication:** HIV infection leads to increased ROS production within infected immune cells, such as macrophages and lymphocytes, as part of the host immune response. These elevated ROS levels contribute to oxidative damage of hematopoietic cells within the bone marrow, impairing their function and survival.⁸⁻⁹
- 2. Immune Dysregulation:** Chronic immune activation and dysregulation in HIV-infected individuals further exacerbate oxidative stress. Pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), stimulate ROS production and disrupt redox balance, leading to oxidative damage of bone marrow cells.¹⁰⁻¹¹
- 3. Antiretroviral Therapy (ART):** While ART is essential for suppressing viral replication and restoring immune function in HIV-infected individuals, certain antiretroviral drugs can induce oxidative stress.¹³ Nucleoside reverse

transcriptase inhibitors (NRTIs) like zidovudine (AZT) and protease inhibitors have been implicated in ROS generation and mitochondrial dysfunction, contributing to hematologic toxicity and bone marrow suppression.

Impact on Hematopoiesis

Oxidative stress exerts detrimental effects on hematopoietic stem and progenitor cells, compromising their ability to maintain hematopoietic homeostasis. ROS-induced DNA damage, lipid peroxidation, and protein oxidation lead to apoptosis and senescence of hematopoietic cells, resulting in bone marrow failure and pancytopenia. Additionally, oxidative stress disrupts the bone marrow microenvironment, impairing hematopoietic stem cell niches and niche-supporting cells, further exacerbating hematopoietic dysfunction.¹²

Therapeutic Implications

Targeting oxidative stress holds promise as a therapeutic strategy for managing AA in HIV-infected individuals.¹³ Antioxidant therapies, such as N-acetylcysteine (NAC), alpha-lipoic acid (ALA), and vitamin E, aim to scavenge ROS and restore redox balance in the bone marrow microenvironment. By mitigating oxidative damage to hematopoietic cells, these agents have the potential to preserve hematopoietic function and alleviate pancytopenia. Additionally, strategies aimed at reducing viral replication and immune activation may indirectly alleviate oxidative stress and mitigate its detrimental effects on bone marrow function.

Role of Inflammation

Inflammation is a pivotal component of the pathogenesis of aplastic anemia (AA) in individuals living with HIV, exerting multifaceted effects on bone marrow function and hematopoiesis.¹⁵ Chronic immune activation and dysregulation, characteristic of HIV infection, contribute to an inflammatory milieu that disrupts hematopoietic homeostasis, promotes immune-

mediated destruction of hematopoietic cells, and exacerbates bone marrow failure.

Mechanisms of Inflammation in HIV-Associated AA

1. **Cytokine Dysregulation:** HIV infection leads to the dysregulation of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF- α), interleukin-6 (IL-6), and interferon-gamma (IFN- γ). Elevated levels of these cytokines promote immune activation and stimulate inflammatory pathways within the bone marrow, inhibiting hematopoiesis and impairing the function of hematopoietic stem and progenitor cells.¹²

2. **Autoimmune Mechanisms:** HIV-associated immune dysregulation can trigger autoimmune responses targeting hematopoietic cells. Autoantibodies directed against hematopoietic progenitors and mature blood cells contribute to their destruction, further exacerbating pancytopenia and bone marrow failure.¹⁶

3. **Microbial Translocation:** HIV-induced damage to the intestinal mucosa results in microbial translocation, leading to the systemic release of microbial products such as lipopolysaccharide (LPS). These microbial products activate innate immune pathways, including Toll-like receptor (TLR) signaling, and perpetuate chronic inflammation, exacerbating bone marrow dysfunction.¹⁷⁻¹⁹

Inflammation disrupts the delicate balance of hematopoietic homeostasis, impairing the function of hematopoietic stem and progenitor cells and compromising bone marrow function.²⁰ Pro-inflammatory cytokines inhibit hematopoiesis by inducing apoptosis of hematopoietic progenitor cells, suppressing their proliferation, and disrupting the bone marrow microenvironment. Additionally, immune-mediated destruction of hematopoietic cells exacerbates pancytopenia, contributing to the clinical manifestations of AA

in HIV-infected individuals. Targeting inflammation represents a promising therapeutic approach for managing AA in individuals living with HIV. Anti-inflammatory agents, such as corticosteroids, TNF- inhibitors, and IL-6 receptor antagonists, aim to suppress pro-inflammatory cytokine production and mitigate immune-mediated damage to hematopoietic cells. These agents have the potential to alleviate bone marrow dysfunction, reduce the severity of pancytopenia, and improve hematologic parameters in HIV-associated AA.

Impact on Hematopoiesis

Oxidative stress and inflammation exert profound effects on hematopoiesis in individuals with aplastic anemia (AA) and HIV infection, disrupting the delicate balance of bone marrow function and compromising the production of blood cells. These pathogenic mechanisms contribute to bone marrow failure, pancytopenia, and immune dysregulation, exacerbating the clinical manifestations of AA and HIV. Oxidative stress leads to damage to hematopoietic stem cells (HSCs), compromising their self-renewal capacity and differentiation potential. ROS-induced DNA damage and mitochondrial dysfunction impair HSC function, contributing to the depletion of hematopoietic progenitors and the development of pancytopenia. Elevated levels of ROS induce apoptosis and senescence of hematopoietic progenitor cells, leading to their premature depletion and impaired hematopoiesis. ROS-mediated activation of pro-apoptotic pathways and DNA damage response pathways further exacerbates bone marrow dysfunction. Oxidative stress disrupts the bone marrow microenvironment, impairing the function of niche-supporting cells and hematopoietic stem cell niches. ROS-mediated damage to stromal cells and endothelial cells alters cytokine production and adhesion molecule expression, further compromising hematopoietic homeostasis.^{12-13, 21-22}

Inflammation

Pro-inflammatory cytokines, such as TNF- , IL-6, and IFN- , inhibit hematopoiesis by inducing apoptosis of hematopoietic progenitor cells and suppressing their proliferation.²³ Dysregulated cytokine signaling disrupts the balance between hematopoietic stem cell self-renewal and differentiation, leading to bone marrow failure and pancytopenia. Inflammatory processes contribute to autoimmune mechanisms targeting hematopoietic cells, leading to their immune-mediated destruction within the bone marrow. Autoantibodies directed against hematopoietic progenitors and mature blood cells further exacerbate pancytopenia and compromise hematopoietic function. Chronic inflammation resulting from microbial translocation perpetuates immune activation and dysregulation, exacerbating bone marrow dysfunction. Microbial products, such as LPS, activate innate immune pathways and stimulate inflammatory responses, further impairing hematopoiesis in individuals with HIV-associated AA.²⁴ Oxidative stress and inflammation collectively disrupt hematopoietic homeostasis, impairing the function of hematopoietic stem and progenitor cells and compromising bone marrow function in individuals with AA and HIV infection.²⁵ These pathogenic mechanisms contribute to the development of pancytopenia, immune dysregulation, and bone marrow failure, exacerbating the clinical manifestations of both conditions.

Therapeutic Strategies

Managing aplastic anemia (AA) in individuals with HIV requires a multifaceted approach that addresses the underlying pathogenic mechanisms, including oxidative stress and inflammation. Several therapeutic strategies targeting these mechanisms hold promise for mitigating bone marrow dysfunction, preserving hematopoietic function, and improving patient outcomes.

Antioxidant Therapies

1. **N-Acetylcysteine (NAC):** NAC is a precursor of glutathione, a potent antioxidant involved in ROS scavenging. By replenishing intracellular glutathione levels, NAC mitigates oxidative stress and protects hematopoietic cells from ROS-induced damage. Clinical studies have shown potential benefits of NAC in reducing oxidative stress and improving hematologic parameters in AA with HIV.²⁶

2. **Alpha-Lipoic Acid (ALA):** ALA is a powerful antioxidant that scavenges free radicals and regenerates other antioxidants, including glutathione and vitamins C and E. ALA has demonstrated cytoprotective effects against oxidative stress-induced damage in various tissues, including the bone marrow. Its potential role in mitigating oxidative stress and preserving hematopoietic function warrants further investigation in the context of HIV-associated AA.

Anti-Inflammatory Agents

1. **Corticosteroids:** Corticosteroids exert immunosuppressive and anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and modulating immune responses. In the treatment of AA with HIV, corticosteroids may help suppress immune-mediated destruction of hematopoietic cells and alleviate bone marrow inflammation. However, their long-term use is associated with adverse effects, necessitating careful monitoring.¹⁵

2. **Tumor Necrosis Factor-Alpha (TNF-) Inhibitors:** TNF- is a key pro-inflammatory cytokine implicated in the pathogenesis of AA and HIV-associated immune dysregulation. TNF- inhibitors, such as infliximab and adalimumab, block TNF- signaling and attenuate inflammatory responses. These agents have shown efficacy in certain autoimmune disorders and may hold potential for mitigating inflammation and improving hematopoiesis in HIV-associated AA.¹⁶

Immunomodulatory Therapies

1. **Thymoglobulin:** Thymoglobulin is a polyclonal antibody preparation targeting T lymphocytes, which play a central role in the pathogenesis of AA and HIV-associated immune dysregulation.²⁷ By depleting T cells and modulating immune responses, thymoglobulin may alleviate immune-mediated destruction of hematopoietic cells and restore hematopoietic function in AA with HIV. However, its use is associated with risks of infection and immunosuppression.

2. **Regulatory T Cell (Treg) Therapy:** Tregs play a crucial role in immune tolerance and regulation. Augmenting Treg function or numbers may help restore immune homeostasis and mitigate autoimmune responses in AA with HIV. Strategies to expand and infuse ex vivo-generated Tregs are under investigation as potential therapeutic interventions for immune-mediated hematologic disorders.²⁸⁻²⁹

Conclusion

The management of aplastic anemia (AA) in individuals with HIV requires a comprehensive approach that addresses the underlying pathogenic mechanisms, including oxidative stress and inflammation. The intricate interplay between these factors contributes to bone marrow dysfunction, pancytopenia, and immune dysregulation, exacerbating the clinical manifestations of both conditions. Therapeutic strategies targeting oxidative stress and inflammation offer promising avenues for preserving hematopoietic function and improving patient outcomes. Antioxidant therapies such as N-acetylcysteine (NAC) and alpha-lipoic acid (ALA) aim to mitigate oxidative stress and protect hematopoietic cells from ROS-induced damage. Meanwhile, anti-inflammatory agents like corticosteroids and tumor necrosis factor-alpha (TNF-) inhibitors suppress immune-mediated destruction of hematopoietic cells and alleviate bone marrow inflammation. Immunomodulatory

therapies such as thymoglobulin and regulatory T cell (Treg) therapy offer additional strategies to restore immune homeostasis and mitigate autoimmune responses. While these therapeutic interventions hold promise, further research is needed to elucidate their efficacy, safety, and optimal use in the context of HIV-associated AA. Clinical studies are warranted to evaluate the long-term outcomes and potential adverse effects of these therapies in affected individuals. Additionally, a multidisciplinary approach involving hematologists, infectious disease specialists, and immunologists is essential for guiding treatment decisions and optimizing patient care.

References

1. Boddu PC, Kadia TM. Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. *Expert review of hematology*. 2017;10(5):433-448.
2. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review*. *Newport International Journal of Public Health and Pharmacy (Nijpp)*. 2023;3(2):64-67.
3. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
4. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22
5. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian J Dental Health Sci*. 2024; 30];3(2):7-14.
<http://ajdhs.com/index.php/journal/article/view/39>
6. Ivanov AV, Valuev-Elliston VT, Ivanova ON, Kochetkov SN, Starodubova ES, Bartosch B, Isaguliants MG. Oxidative stress during HIV infection: mechanisms and consequences. *Oxidative medicine and cellular longevity*. 2016;2016.
7. González-Blanco I, Calás-Hechavarria V, Gravier-Hernández R, Pérez-Correa D, Reyes-Pérez A, Hernández-Requejo D, Guevara-García M, García-Mir V, Gil-del Valle L, León-Fernández OS, Pérez-Ávila LJ. Oxidant/antioxidant status in subjects with HIV infection in different clinical conditions. *Biomedicine & Aging Pathology*. 2014;4(3):235-242.
8. Salmen S, Berrueta L. Immune modulators of HIV infection: the role of reactive oxygen species. *J Clin Cell Immunol*. 2012;3(121):2.
9. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
10. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. *Viruses*. 2019;11(3):200.
11. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30
12. Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. *Current HIV research*. 2014;12(1):13-21.
13. Mathys L, Balzarini J. The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications. *Expert opinion on therapeutic targets*. 2016;20(1):123-143.

14. Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ. When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms. *Frontiers in Immunology*. 2024; 15:1339971.
15. Obeagu EI. Immunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. *Elite Journal of Health Science*. 2023;1(1):14-24.
16. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy. *Elite Journal of Medicine*. 2024;2(4):19-36.
17. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
18. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
19. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.21960/jphn.v6i2.141).
20. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immuno-modulation of hematopoietic stem and progenitor cells in inflammation. *Frontiers in immunology*. 2020; 11:585367.
21. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38. DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
22. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.21960/jphn.v5i6.129).
23. Jahandideh B, Derakhshani M, Abbaszadeh H, Movassaghpour AA, Mehdizadeh A, Talebi M, Yousefi M. The pro-Inflammatory cytokines effects on mobilization, self-renewal and differentiation of hematopoietic stem cells. *Human Immunology*. 2020;81(5):206-217.
24. Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. *Physiological reviews*. 2020;100(2):603-632.
25. Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ. When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms. *Frontiers in Immunology*. 2024; 15:1339971.
26. Safe IP, Amaral EP, Araujo-Pereira M, Lacerda MV, Printes VS, Souza AB, Beraldi-Magalhaes F, Monteiro WM, Sampaio VS, Barreto-Duarte B, Andrade AM. Adjunct N-acetylcysteine treatment in hospitalized patients with HIV-associated tuberculosis dampens the oxidative stress in peripheral blood: Results from the RIPENACTB study trial. *Frontiers in immunology*. 2021; 11:602589.
27. Iriart X, Le Bouar M, Kamar N, Berry A. Pneumocystis pneumonia in solid-organ transplant recipients. *Journal of Fungi*. 2015;1(3):293-331.

28. Adias TC, Erhabor O. Human Immunodeficiency Virus Testing Algorithm in Resource Limiting Settings. In Current Perspectives in HIV Infection 2013: 480. Rijeka: InTech.
29. Jeremiah ZA, Obazee Y, Okogun GR, Adias TC, Mgbere O, Essien EJ. Impact of short-term antiretroviral therapy (START) on some fibrinolytic markers in HIV-infected Nigerian adults: preliminary findings from the START study. HIV/AIDS-Research and Palliative Care. 2012:87-94.

Access this Article in Online	
	Website: www.ijcrps.com
	Subject: Immunology
Quick Response Code	
DOI: 10.22192/ijcrps.2024.11.05.002	

How to cite this article:

Emmanuel Ifeanyi Obeagu and Teddy Charles Adias. (2024). Aplastic Anemia in HIV: Role of Oxidative Stress and Inflammation. Int. J. Curr. Res. Chem. Pharm. Sci. 11(5): 15-22.

DOI: <http://dx.doi.org/10.22192/ijcrps.2024.11.05.002>